Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Digestive System Diseases

Gland and Hormone Related Diseases

Skin and Connective Tissue Diseases

Rare Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Carcinoma, Squamous Cell

Prostatic Neoplasms

Stomach Neoplasms

Esophageal Neoplasms

Pancreatic Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Urinary Bladder Neoplasms

Melanoma

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Endocrine Gland Neoplasms

Pancreatic Diseases

Endocrine System Diseases

Stomach Cancer

Esophageal Cancer

Pancreatic Cancer

Ovarian Cancer

Ovarian Epithelial Cancer

All Drugs and Chemicals

Antibodies

Antibodies, Monoclonal

Immunoglobulins

NGM120

Placebo

NGM Study Director

Study of NGM120 in subjects with advanced solid tumors and and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 5.0 and is considered by the investigator to be clinically relevant and attributed to the study treatment during the first 28 days after the first dose of study treatment.

Number of patients with adverse events (AEs) according to severity, seriousness, and relationship to study drug

Number of patients with clinically significant change from baseline in laboratory abnormalities as characterized by type, frequency, severity (graded by CTCAE version 5.0) and timing.

Pharmacokinetics (PK) of NGM120 by measuring serum concentration of NGM120 at specified timepoints

Immunogenicity against NGM120 by measuring percentage of subjects to develop antidrug antibodies and neutralizing antibodies

Assessment of Antitumor and Anticachexia Activity Assessed using the RECIST Version 1.1 criteria

Body weight during therapy with NGM120 by measuring change in body weight (in lb).

Skeletal muscle index during therapy with NGM120 by measuring skeletal muscle mass and adiposity at level of L3 on serial CT scan.

NGM Biopharmaceuticals, Inc

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy	NCT04068896	Pancreatic Canc... Metastatic Cast... Bladder Cancer Melanoma Non-small Cell ... Colorectal Canc... Gastric Cancer Esophageal Canc... Ovarian Cancer Head Neck Squam... Prostate Cancer	NGM120 NGM120 NGM120 NGM120 NGM120 NGM120 Placebo	18 Years -	NGM Biopharmaceuticals, Inc
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy	NCT04068896	Pancreatic Canc... Metastatic Cast... Bladder Cancer Melanoma Non-small Cell ... Colorectal Canc... Gastric Cancer Esophageal Canc... Ovarian Cancer Head Neck Squam... Prostate Cancer	NGM120 NGM120 NGM120 NGM120 NGM120 NGM120 Placebo	18 Years -	NGM Biopharmaceuticals, Inc

Spots Global Cancer Trial Database for head neck squamous cell carcinoma